Objective. To assess the heart rate turbulence (HRT) in patients with SSc as a method of assessment for cardiac autonomic nervous function.
Introduction
Various cardiovascular complications may occur as a natural clinical sequel of SSc, including dysrhythmias, pulmonary hypertension and autonomic nervous system (ANS) dysfunction [1, 2] . The cardiac ANS imbalance manifested by an impaired heart rate turbulence (HRT) and/or heart rate variability (HRV) was reported to be a significant risk factor for malignant ventricular arrhythmia and sudden cardiac death in patients after myocardial infarction or with congestive heart failure [3, 4] . Patients with SSc are also at risk of arrhythmia-related sudden death [5] . HRT, a novel electrophysiological phenomenon, is a biphasic, acceleration-deceleration reaction of the sinus node to a ventricular premature beat (VPB) occurrence. HRT is controlled by the ANS and reflects baroreflex sensitivity [6] . Besides its prognostic value, HRT has also been reported as a useful marker for diabetic autonomic neuropathy [7] . Moreover, HRT can be measured more easily than HRV and interpretation of results is much simpler. However, there are limited data on HRT in SSc. Therefore, we assessed HRT in 24-h Holter monitoring in SSc patients and evaluated the relationship between results of HRT and time-and frequency-domain HRV parameters.
Methods

Study population
Sixty-eight consecutive adult patients with SSc diagnosed according to ACR [8] and/or LeRoy's classification criteria [9] and 42 healthy subjects, specially selected for this study, were examined before inclusion in the study. All examined patients underwent clinical evaluation, 24-h Holter monitoring, ECG, transthoracic echocardiography (Sonos 2000; Hewlett-Packard, Andover, MA, USA), chest X-ray, spirometry and basic laboratory tests. Standard techniques were used to screen all patients for the following serological markers: ANA, ACA and anti-extractable antigen antibodies, including Scl-70 antibodies.
Scleroderma patients with coronary artery disease, congestive heart failure or left ventricular dysfunction (ejection fraction <50%), significant valvular abnormalities and atrial fibrillation or flutter in medical history were not included in the study. Coronary artery disease was excluded when subjects had no angina-type chest discomforts, ischaemia signs in a resting ECG, significant ST episodes during Holter monitoring or segmental abnormalities of left ventricle function in echocardiography. In five patients, less typical discomfort was observed and exercise ECG testing was performed (coronary arteriography was not used). Patients with significant pulmonary function abnormalities (defined by forced vital capacity or forced expiratory volume in 1 s <70% of predicted) were not included either. Patients with diabetes mellitus, impaired renal function defined by a serum creatinine concentration 5132 mmol/l, hepatic or thyroid dysfunction, anaemia and plasma CRP concentration 510 mg/dl were excluded.
Twenty-four-hour Holter monitoring and HRT analysis
All 24-h Holter monitoring was performed on a threechannel digitized recording during normal everyday activities. Evaluation of mean heart rate, the presence of ventricular and supraventricular arrhythmias and HRV analysis were performed (Oxford Medilog Excel 2, Oxford Instruments, Abingdon, UK).
Two quantitative HRT parameters were calculated using HolCard 24W software (Aspel, Poland), i.e. turbulence onset (TO) reflecting the initial phase of sinus rhythm acceleration and turbulence slope (TS) describing the deceleration phase. TO was defined as a percentage difference between the mean of the first two sinus RR intervals in ECG after VPB and the last two RR intervals before VPB. TS was described as a maximum positive slope of a regression line assessed over five consecutive RR intervals within the first 20 sinus RR intervals after VPB. TO was separately calculated for all VPBs and then averaged. TS was calculated based on an averaged local tachogram. Filtering algorithm and manual review were used to eliminate inappropriate electrocardiographic strips. As has been proposed, HRT was considered abnormal when TO was 50.0% and/or TS was 42.5 ms/RR interval [3, 6] .
Typical indices of time and frequency domain analysis were evaluated according to the standards of HRV measurement [10] . Time-domain analysis was performed for the entire recording period. The frequency (spectral) domain analysis was assessed separately for day and night periods. Four 5-min ECG recordings were selected for each day/night period, after which results were added and an average was calculated. Deletions of outlier data were not performed. All tests were double sided. Spearman's correlation was used to assess the relationship between examined parameters. Logistic regression analysis was performed to assess a potential effect of variables on HRT. Univariate and multivariate analyses were performed, and many models were examined. Model selection was based on a fit measure by Akaike's Information Criterion or on area under receiver-operating characteristic analysis, if the examined variable was binary. An influence of measured parameters was expressed as an odds ratio (OR). P < 0.05 was considered statistically significant. The analysis was performed using a statistical software package (SAS 9.1, SAS Institute Inc., NC, USA).
Ethical approval
All 68 patients and 42 control subjects expressed their informed consent to take part in the study. Subjects' written consent was obtained according to the Declaration of Helsinki. The study was approved by an independent ethics board (The Bioethics Committee in The Medical University of Warsaw, Poland).
Results
General characteristics of study population
Out of 68 SSc patients, 45 subjects were enrolled in the current study. The remaining 23 persons were excluded due to co-existing disorders (nine patients) or lack of VPBs suitable for calculation of HRT (14 patients). DcSSc was diagnosed in 22 (49%) patients, whereas lcSSc was diagnosed in 23 (51%). Mean disease duration was 11.7 (11.4) (range 1-45) years. ANAs were detected in 29 patients (64%), ACAs in 12 (27%) and anti-Scl-70 in 22 (49%). Pulmonary fibrosis was diagnosed in 15 patients by previously performed high-resolution CT. Mild essential hypertension was found in eight patients. At the time of the study, no patients received b-blockers or nonvasoselective calcium channel blockers. The control group consisted of 30 healthy persons, whose Holter recordings demonstrated VPBs suitable for HRT analysis. Clinical characteristics of study groups are presented in Table 1 .
In all examined subjects, left ventricular systolic function was normal and no myocardial hypertrophy was found. Nine (20%) SSc patients had tricuspid regurgitation with tricuspid regurgitation pressure gradient (TRPG) of >31 mmHg. The maximum value of TRPG in SSc was 40 mmHg (mild pulmonary hypertension). In the control group, only trivial tricuspid regurgitation was present.
HRT and HRV data
All patients were in sinus rhythm throughout the recording period. Abnormal HRT (TO 50% and/or TS 42.5 ms/RR) was found in 19 (42%) SSc patients and was not detected in controls. Impairment of both TO and TS was observed in 3 patients, only TO in 13 others and only TS in 3 scleroderma patients. Values of TO and TS in study groups are presented in Fig. 1 . A significant negative correlation was found between TO and TS (r = À0.37; P = 0.01). Moreover, SSc duration correlated negatively with values of TS (r = À0.3; P = 0.045). However, it had no significant influence on TO. Parameters of HRT did not differ significantly between groups with dcSSc and lcSSc. The median value of TO was À 0.07 (range À 2.52 to 5.96) in dcSSc patients and À 0.27% (range À 3.81 to 2.15) in lcSSc patients, non-significant (ns). The median TS was 6.78 (1.85-15.62) and 7.00 (2.10-19.5) ms/RR for dcSSc and lcSSc, respectively, ns.
All time-domain parameters evaluated in HRV analysis in SSc patients were significantly lower than in the control group (Table 1) . A significant correlation was demonstrated between SDNN index and TS (r = 0.46; P = 0.001). Time-domain HRV parameters did not differ significantly between dcSSc and lcSSc groups.
In SSc patients, when compared with controls, there were significantly lower values of low-(LF) and high-frequency (HF) power spectra (Table 1 ). Abnormal HRT in SSc patients was related to a reduction in LF, both in day (median: 97.9 vs 283.6 ms 2 ; P = 0.04) and night periods (median: 55.8 vs 187.3 ms 2 ; P = 0.02).
However, abnormal HRT occurrence had no significant influence on the power spectrum of HF. Significant correlations were also demonstrated between HRV spectral analysis and HRT parameters: LF day and TO (r = À0.29; P = 0.047), LF day and TS (r = 0.59; P <0.0001), HF day and TS (r = 0.37; P = 0.01), LF night and TO (r = À0.33; P = 0.03), LF night and TS (r = 0.45; P = 0.002), HF night and TO (r = À0.31; P = 0.04) and LF/HF day and TS (r = 0.45; P = 0.002).
Logistic regression analysis
In SSc patients, uni-and multivariate logistic regression analysis was performed to identify potential predictors of TO and TS values and abnormal HRT occurrence. In multivariate analyses, the only common significant predictor that influenced both TO and TS values and abnormal HRT occurrence was old age. The OR for TO was 1.68 (95% CI 1.1, 2.5; P = 0.01), for TS 1.76 (95% CI 1.1, 2.8; P = 0.02), for abnormal HRT occurrence 1.84 (95% CI 1.1, 3.5; P = 0.03); OR and 95% CI were adjusted for an increase of 10 years. Multivariate analysis also revealed that the occurrence of abnormal HRT in SSc patients was significantly influenced by pulmonary hypertension (OR 6.1; 95% CI 1.1, 48.6; P = 0.049).
Discussion
Currently, HRT and HRV analyses have been proposed by European and American experts as potentially useful tools in the risk stratification of patients at risk of life-threatening ventricular arrhythmias [11] . The prognostic value of blunted HRT reaction is independent of other predictors such as HRV, ventricular arrhythmias or left ventricular ejection fraction. Moreover, data obtained from six retrospective and two prospective large post-myocardial infraction studies proved that HRT was the strongest electrocardiographic risk predictor of subsequent death, exceeding the value of HRV assessment [6] . Numerous studies using time-and spectral-domain HRV or Ewing tests confirmed ANS imbalance in SSc, and especially impaired parasympathetic activity [12, 13] . Fibrosis and inflammation of the heart and small heart nerves are suggested as causal factors. Sympathetic ANS activation resulting from even   FIG. 1 Values of TO and TS in patients with SSc and controls. The median TO in SSc is À0.13% (range À3.81% to 5.96%), in controls À2.45% (range À5.56% to À0.35%), P = 0.0001. The median TS in SSc is 6.90 (range 1.85-19.5) ms/RR and in healthy persons 13.21 (range 2.77-47.9) ms/RR, P = 0.0003.
subclinical heart failure and a subsequent recruitment of baroreceptors may also be important causal factors. Ferri et al. [14] performed HRV analysis in 24-h Holter monitoring in 30 adult patients with SSc. As compared with healthy controls, values of time-and spectral-domain parameters were significantly lower in SSc patients. Moreover, Cox regression model analysis revealed a predictive value of spectral power values of LF and HF for mortality in SSc patients [14] .
Our study confirms the frequent occurrence of ANS dysfunction in SSc. Both TO and TS values were more impaired in the dcSSc than lcSSc group, but the differences were not significant. Interestingly, HRT deteriorates with disease duration, which suggests progressive, scleroderma-related ANS dysfunction. HRT impairment also confirms diminished baroreflex sensitivity in SSc patients, as previously suggested on the basis of HRV measurement by Pancera et al. [15] . Our findings are in line with the results reported by Balcioglu et al. [7] in patients with diabetes mellitus. In this study, sensitivity of HRT and time-domain HRV assessment for the detection of cardiac autonomic neuropathy was similar (frequencydomain HRV was not performed).
Sudden cardiac death is not very common in SSc, but some reports suggest it happens much more frequently than was once thought [16, 17] . In one patient with dcSSc and significant ANS dysfunction (TO +0.21% and TS 2.38 ms/RR), we observed very frequent non-sustained ventricular tachycardia. The patient died suddenly 9 months after HRT measurement.
A potential limitation of HRT analysis is the mandatory presence of VPBs. If assessment of ANS function in subjects without VPBs seems to be absolutely needed, it might be evaluated by HRV. However, patients without ventricular arrhythmias have a relatively good survival prognosis, irrespective of the assessment of ANS function. In our study, nine patients with SSc were also excluded due to co-existing disorders. Such large restrictions for inclusion in the study were necessary to avoid any well-known conditions influencing ANS function, except scleroderma. Another potential limitation is that our study is observational research with a relatively low number of included cases.
A possible difficulty in the wide ambulatory care of SSc patients might also be the availability of HRT assessment. However, in professional Holter monitoring laboratories the evaluation of HRT should be easily available. Especially, HRT measurement procedure should not be more expensive than HRV (depending on local conditions).
Conclusions
The results of this study demonstrate that patients with SSc develop cardiac ANS dysfunction, which is confirmed by HRT impairment. The hypothesis that diminished HRT could be considered as an independent risk factor for mortality in SSc needs further investigation. Until then, we judge that there are no adequate scientific data for making a decision about recommendation for necessity of HRT assessment in all SSc subjects. However, measurement of HRT should be considered in some patients after detailed clinical, echocardiographical and standard ECG Holter monitoring evaluations.
Rheumatology key messages
. HRT is impaired in SSc. . HRT assessment may be used as a new method for the detection of cardiac autonomic dysfunction in SSc.
